Augmented renal clearance

Arthur J. Atkinson, Jr.*

Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

*Correspondence: Arthur J. Atkinson, Jr.; E-mail: art_atkinson@msn.com

Introduction

In 1974, Lucius Dettle proposed using creatinine clearance to estimate appropriate drug doses for patients with impaired renal function and a lowered glomerular filtration rate (GFR).[1] This likely represents the greatest clinical contribution that pharmacokinetics continues to make to the individualization of pharmacotherapy.[2] By contrast, attention has only recently been focused on the phenomenon of augmented renal clearance (ARC), which has only recently been widely recognized and its pathogenesis remains incompletely understood. However, ARC has been shown to result in increased dose requirements for drugs that are primarily eliminated by renal excretion, including many antimicrobial agents and enoxaparin. Recognition of ARC is hampered by the fact that the standard creatinine-based equations used to estimate renal function are not accurate in this clinical setting and the diagnosis is best established using both serum and urine creatinine measurements to calculate clearance. So a high index of clinical suspicion and awareness is usually required before this step is taken to confirm the diagnosis of ARC.

Addition to the complexity of caring for critically ill patients is the fact that many of them have a creatinine clearance that exceeds 130 mL/min/1.73 m². This phenomenon, termed augmented renal clearance (ARC), has only recently been widely recognized and its pathogenesis remains incompletely understood. However, ARC has been shown to result in increased dose requirements for drugs that are primarily eliminated by renal excretion, including many antimicrobial agents and enoxaparin. Recognition of ARC is hampered by the fact that the standard creatinine-based equations used to estimate renal function are not accurate in this clinical setting and the diagnosis is best established using both serum and urine creatinine measurements to calculate clearance. So a high index of clinical suspicion and awareness is usually required before this step is taken to confirm the diagnosis of ARC.

Keywords
Antimicrobial agents,
Augmented renal clearance,
Critically ill patients,
Drug dose requirements

pISSN: 2289-0882
eISSN: 2383-5427

Recognition of ARC

The incidence of ARC has been reported to range from 30% in patients after abdominal surgery[15] to 100% in patients with subarachnoid hemorrhage,[12] with an incidence of 55.8% in a general intensive care unit population.[14] Serum creatinine measurements have been within the normal range in all ARC patients.[8] So actual measurement of creatinine clearance is considered essential to making the diagnosis and both 8-hour[9] and 24-hour urine collections[6,7,10-12] have been used. Loirat et al.[6] found that creatinine clearance agreed closely with inulin and iothalamate clearance in this setting, and thus serves in these patients as a reliable measure of GFR. On the other hand, the serum creatinine-based equations that are routinely used to estimate renal function have been repeatedly shown to provide poor estimates of GFR in patients with ARC.[7,17-19]

Most studies have found that ARC is more common in
Augmented renal clearance

Younger patients who are less than 50 years of age than in patients who are older.[8] Udy et al.[13] have measured cardiac index in ARC patients with sepsis or trauma and have found it somewhat correlated with creatinine clearance in septic patients but not well correlated in trauma patients. A number of authors have examined the relationship between various severity of illness scores and the occurrence of ARC.[8,10] However, the identification of patients with ARC remains challenging and no satisfactory substitute has yet been found for actually measuring creatinine clearance.

**Mechanism underlying ARC**

Brown et al.[20] evaluated creatinine clearance and cardiac index in 50 surgical intensive care patients who had been admitted for trauma or nontraumatic surgical emergencies. Creatinine clearance was elevated in patients who did not develop renal failure and the extent of elevation was significantly correlated with cardiac index but ARC was not seen in patients who were more than 50 years old. These authors concluded that the increase in creatinine clearance represented part of a normal recovery response in younger patients. Udy et al.[21] extended these observations by using sinistrin and para-aminohippuric acid (PAH) as respective markers for GFR and effective renal plasma flow and demonstrated that both of these parameters were elevated in patients with ARC. Although both tubular anion secretion of PAH and tubular reabsorption of fluconazole were increased, tubular cationic secretion of pindolol was reduced. Udy[22] also reported that changes in creatinine clearance generally paralleled changes in cardiac output in ARC patients.

Both cardiac output and GFR increase as part of the normal physiological response to pregnancy.[23] However, the increase in cardiac output occurs subsequent to the initial increase in GFR which results from widespread peripheral vasodilation. A similar sequence of events in other settings of ARC has been attributed to the systemic inflammatory response syndrome (SIRS).[24] Although the concept of SIRS was initially developed to help characterize patients with sepsis, it has subsequently been found to be equally applicable to patients with burns and other trauma in which an initial injury leads to the subsequent release of multiple cytokine mediators of inflammation that cause widespread vasodilation.[25] Further stimuli that could increase cardiac output in critically ill patients include administration of fluids and drugs such as dopamine.[24] This concept of pathophysiology has led to the schema shown in Figure 1.

Udy et al.[22] found that atrial natriuretic peptide (ANP) plasma concentrations were also increased in patients with traumatic brain injury. They speculated that this could be contributing to the ARC observed in brain injury patients since ANP is known to increase both GFR and renal sodium excretion.[26] However, sequential measurements of creatinine clearance and ANP concentrations in individual patients indicated that there was an inverse relationship between changes in creatinine clearance and ANP concentrations. They concluded that intravascular volume and atrial wall stretch decreased as GFR increased, thus causing ANP secretion to be decreased.

Activation of renal functional reserve has also been postulated to contribute to ARC.[21] The existence of renal functional reserve was first identified by Shannon, Jolliffe, and Smith[27] who noted a marked increase in GFR after dogs were fed a high protein meal. This phenomenon has since been studied extensively and Molitoris[28] feels that basal GFR measurements do not adequately characterize kidney function because they do not take renal functional reserve into account. Although it has been demonstrated in pregnant women that renal functional reserve is normal, and thus has not been activated by pregnancy itself,[16] similar studies have not been conducted in other categories of patients with ARC. So this remains one of the factors that may be contributing, probably in combination with other factors, to what appears to be a fairly general response to injury.

**Clinical consequences of ARC**

ARC is generally considered to be a favorable marker of a host’s ability to respond to injury.[8] So the main concern is that the increased renal function will lead to suboptimal therapy...
with drugs that are primarily eliminated by renal excretion. In fact, the need for burn patients to receive increased doses of gentamicin[4] and amikacin[5] was noted even before Loirat et al.[6] reported that an increase in GFR required increased tobramycin doses in this clinical setting. The clinical impact of ARC has largely been reported in the context of antimicrobial therapy, not only with aminoglycosides, but also with vancomycin[29] and β-lactams.[30] In addition, patients with ARC have also been found to have a shorter duration of anticoagulant effect when standard doses of enoxaparin were administered.[31]

Although it seems intuitively obvious that ARC should lead to an increased rate of treatment failure unless doses of renally excreted drugs are appropriately increased, conflicting results have been reported in the few outcome studies that have been conducted. An initial study reported by Claus et al.[32] did find that antibiotic failures were more common in critically ill patients with ARC than in those with lower measured creatinine clearance. Thus, therapeutic failure was present for 33.3% of patients with ARC that lasted for more than one day, for 17.4% of patients with transient ARC that lasted for only one day but for just 12.9% of patients without ARC. The authors excluded aminoglycosides, teicoplanin, and vancomycin because therapeutic drug monitoring (TDM) was used to adjust doses of these antibiotics, but TDM was not used for the β-lactams, quinolone, and other antibiotics that were included in the study.

More recent outcome studies have focused solely on β-lactam antibiotics and have yielded conflicting results. Hutter et al.[33] studied 100 critically ill patients with clinically suspected or microbiologically proven severe bacterial infections. TDM was employed and intermediate and trough antibiotic concentrations were compared with the non-species-related breakpoints published by the European Committee on Antimicrobial Susceptibility Testing (EUCAST).[34] Standard antibiotic doses were administered and patients with ARC at study inclusion were found to be 3.3 times more likely to have at least one undetectable β-lactam trough concentration (≤0.2 μg/mL). However neither the presence of ARC nor extremely low trough β-lactam concentrations were significantly associated with clinical failure. The authors reasoned that their use of antibiotics in addition to β-lactams and the fact that organism minimum inhibitory concentrations (MICs) were not measured, and might have been less than 0.2 μg/mL, both might have contributed to these surprising results. Further confounding the analysis of their results is the fact that the underlying prognosis of patients with ARC is generally more favorable than that of patients with lower creatinine clearances.

Udy et al.[35] in an analysis of 254 patients with severe sepsis, also found that ARC did not compromise the efficacy of either intermittent or continuous infusion of β-lactam antibiotics. In fact, clinical cure, defined by patient response observed 14 days after stopping antibiotic therapy, was more common in ARC patients than in those with lower creatinine clearances. Unfortunately, interpretation of these results is clouded by the facts that antibiotic doses, antibiotic plasma concentrations, or susceptibility of the infecting organisms to the administered antibiotics were not reported.

Carrie[30] recently reported a study of 79 critically ill patients with sepsis but without renal failure who were treated with continuous intravenous infusions of standard doses of β-lactam antibiotics. The MIC of the infecting organisms was either measured or estimated from the EUCAST clinical breakpoints. Non-protein bound (free) antibiotic concentrations were measured during the first three days of therapy. Although 44 of the 79 patients had a creatinine clearance ≥ 150 mL/min, none of the patients had measured antibiotic concentrations below the MIC of the known pathogen. On the other hand, taking free concentrations of ≥ 4 times the MIC as a target for maximal efficacy, patients with creatinine clearance values ≥ 170 mL/min were statistically more likely to be under dosed, with a β-lactam subexposure rate of 20%. Those patients with β-lactam subexposure had a higher rate of secondary acquisition of β-lactam resistance and therapeutic failure. The interpretation of these results is again complicated by the frequent administration of combination antibiotic therapy and the underlying better prognosis of ARC patients. In addition to MIC measurements, some indication of bacterial load as well as TDM should probably also be incorporated in future studies.[36]

The presumption is that ARC may adversely impact the effectiveness of any drugs that depend primarily on renal excretion for their elimination. Udy et al.[37] have pointed out that “you only find what you look for” and have emphasized that the finding of a normal serum creatinine concentration does not equate to normal renal function in the setting of ARC. So a high index of suspicion needs to be maintained if ARC is to be diagnosed so that critically ill patients can be treated appropriately. Once ARC is diagnosed, TDM, if available, might be helpful in treating these patients with a number of drugs that are primarily eliminated by renal excretion.

Acknowledgments
None.

Conflict of interest
- Authors: Nothing to declare
- Reviewers: Nothing to declare
- Editors: Nothing to declare

References
1. Detti L. Individualization of drug dosage in patients with renal disease. Med Clin North Am 1974;58:977-985.
2. Atkinson AJ Jr, Huang SM. Nephropharmacology: Drugs and the kidney. Clin Pharmacol Ther 2009;86:453-456. doi: 10.1038/clpt.2009.191.
3. Baptista JP, Udy AA. Augmented renal clearance in critical illness: "The Elephant in the ICU". Minerva Anestesiolog 2015; 81:1050-1052.
4. Zaske DE, Sawchuk RJ. Gerding DN, Strate RG. Increased dosage requirements of gentamicin in burn patients. J Trauma 1976;16:824-828.
5. Zaske DE, Sawchuk RJ, Strate RG. The necessity of increased doses of amikacin in burn patients. Surgery 1978;84:603-608.
Augmented renal clearance

6. Loirat P, Rohan J, Baillet A, Beaufils F, David R, Chapman A. Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin. N Engl J Med 1978;299:915-919.

7. Ruiz S, Minville V, Asehnoune K, Virtos M, Georges B, Fourcade O, et al. Screening of patients with augmented renal clearance in ICU: taking into account the CKD-EPI equation, the age, and the cause of admission. Ann Intensive Care 2015;5:49. doi: 10.1186/s13631-015-0090-8.

8. Bilbao-Mesegue I, Rodriguez-Gascón A, Arraseta H, Isla A, Solinís MA. Augmented renal clearance in critically ill patients: A systematic review. Clin Pharmacokinet 2018;57:1107-1211. doi:10.1007/s40262-018-0636-7.

9. Udy AA, Jarrett P, Lassig-Smith M, Stuart J, Starr T, Dunlop R, et al. Augmented renal clearance in traumatic brain injury: a single-center observational study of atrial natriuretic peptide, cardiac output, and creatinine clearance. J Neurotrauma 2017;34:137-144. doi: 10.1089/neu.2015.4328.

10. Barletta JF, Mangram AJ, Byrne M, Sucher JF, Hollingworth AK, Ali-Osman FR, et al. Identifying augmented renal clearance in trauma patients: Validation of the augmented renal clearance in trauma intensive care scoring system. J Trauma Acute Care Surg 2017;82:665-671. doi: 10.1097/TA.0000000000001387.

11. Lautrette A, Phan TN, Ouchchane L, Aït-Hassan A, Tisier V, Heng AE, et al. High creatinine clearance in critically ill patients with community-acquired acute infectious meningitis. BMC Nephrol 2012;13:124. doi: 10.1186/1471-2369-13-124.

12. May CC, Arora S, Parli SE, Fraser JF, Bastin MT, Cook AM. Augmented renal clearance in patients with subarachnoid hemorrhage. Neurocrit Care 2015;23:374-379. doi: 10.1007/s12028-015-0127-8.

13. Udy AA, Roberts JA, Shorr AF, Boots RJ, Lipman J. Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients. Crit Care 2013;17:R35. doi:10.1186/cc12544.

14. De Waele JJ, Dumoulin A, Janssen A, Hoste EA. Epidemiology of augmented renal clearance in mixed ICU patients. Minerva Anestesiol 2015;81:1079-1085.

15. Declercq P, D’Souza E, Van Wijngaerden E, Wolthuis A, de Buck van Overstraeten A, et al. Augmented renal clearance in non-critically ill patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomized placebo-controlled, clinical trial. Int J Antimicrob Agents 2015;45:385-392. doi: 10.1016/j.ijantimicag.2014.12.017.

16. Lautrette A, Phan TN, Ouchchane L, Aït-Hassan A, Tisier V, Heng AE, et al. High creatinine clearance in critically ill patients with community-acquired acute infectious meningitis. BMC Nephrol 2012;13:124. doi: 10.1186/1471-2369-13-124.

17. Baptista JP, Sousa E, Martins PJ, Pimentel JM. Augmented renal clearance in septic patients and implications for vancomycin optimization. Int J AntimicrobAgents 2012;39:420-423. doi: 10.1016/j.ijantimicag.2011.12.011.

18. Huttner A, Von Dach E, Renzoni A, Huttner BD, Affaticati M, Pagani L, et al. Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of β-lactams administered by continuous infusion: a prospective observational study. Int J Antimicrob Agents 2018;51:443-449. doi: 10.1016/j.ijantimicag.2017.11.013.

19. Abdel El Naeem HEM, Abdelhamid MHE, Atteya DAM. Impact of augmented renal clearance on enoxaparin therapy in critically ill patients. Egypt J Anesth 2017;33:113-117.

20. Claus BO, Hoste EA, Colpaert K, Robays H. Decaycynaere J, De Waele JJ. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. J Crit Care 2013;28:695-700. doi: 10.1016/j.jcrc.2013.03.003.

21. Huttner A, Von Dach E, Renzoni A, Huttner BD, Affaticati M, Pagani L, et al. Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: An observational prospective cohort study. Int J AntimicrobAgents 2015;45:385-392. doi: 10.1016/j.ijantimicag.2014.12.017.

22. European Commission on Antimicrobial Susceptibility Testing. Internet at: http://www.eucast.org/clinical.breakpoints/ Accessed 17 May 2018

23. Udy AA, Dawhurst JM, Roberts JA, Davis JS, Web SAR, Bellomo R, et al. Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomized placebo-controlled, clinical trial. Int J Antimicrob Agents 2017;49:624-630. doi: 10.1016/j.ijantimicag.2016.12.022.

24. Udy AA, De Waele JJ, Lipman J. Augmented renal clearance and therapeutic monitoring of β-lactams. Int J AntimicrobAgents 2015;45:331-333. doi: 10.1016/j.ijantimicag.2014.12.020.

25. Udy AA, Roberts JA, Boots RJ, Lipman J. You only find what you look for: the importance of high creatinine clearance in the critically ill. Anaesth Intensive Care 2009;27:11-13.